At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Lenalidomidedrug
Likely dose
Lenalidomide 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary & Follicular Thyroid Carcinomas
In Brief
A Phase 2 clinical trial evaluating Lenalidomide for Thyroid Neoplasms. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The primary objective of the study is to assess the anti-tumor activity of REVLIMID® (lenalidomide), administered as a single agent, in patients with distantly metastatic thyroid carcinomas which are unresponsive to systemic radioiodine, in terms of tumor response and response duration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThyroid Neoplasms
CountriesUnited States
CollaboratorsCelgene Corporation
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
First PostedFeb 2006
Primary CompletionJul 2010
TodayJul 2026
First PostedFeb 6, 2006
Enrollment StartFeb 1, 2006
Primary CompletionJul 6, 2010
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 20.4 years ago
Interventions
Lenalidomidedrug
Initial dose is 25 mg/day dose will be adjusted accordingly as needed. Dose range for the study is 5 to 25 mg/day